Skip to main content
Sunshine Biopharma Inc. logo

Sunshine Biopharma Inc. — Investor Relations & Filings

Ticker · SBFM ISIN · US8677817004 LEI · 5299005Y64EHRQDQ2Q25 US Manufacturing
Open in API
Filings indexed 382 across all filing types
Latest filing 2018-06-28 Director's Dealing
Country US United States of America
Listing US SBFM

About Sunshine Biopharma Inc.

https://www.sunshinebiopharma.com/

Sunshine Biopharma Inc. is a pharmaceutical company engaged in the research, development, and commercialization of life-saving medicines. The company's primary focus is on various therapeutic areas, with a significant emphasis on oncology and antiviral treatments.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2018-06-28 English
PRIMARY DOCUMENT
Director's Dealing
2018-06-28 English
QUARTERLY REPORT
Interim / Quarterly Report Q1 2018
2018-05-21 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25, which is a Notification of Late Filing submitted to the SEC. It specifically states that the Form 10-Q for the quarter ended March 31, 2018, could not be filed on time and requests an extension. The document does not contain the actual financial data or the 10-Q report itself, but rather a notification about the delay in filing. The document length is 4231 characters, which is relatively short and consistent with a notification rather than a full report. According to the rules, such a notification is classified as a Regulatory Filing (RNS) because it is a compliance document related to filing deadlines and does not contain substantive financial information or the report itself.
2018-05-15 English
ANNUAL REPORT
Annual Report FY 2017
2018-04-02 English
CURRENT REPORT
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated January 1, 2018. It reports the entry into a material definitive agreement, specifically a Share Purchase Agreement to acquire Atlas Pharma Inc. The content focuses on the acquisition transaction details, payment terms, and business description of the acquired company. There are no financial statements or comprehensive financial performance data included. The document is a regulatory announcement of a significant corporate event (acquisition) rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as acquisitions.
2018-01-04 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.